• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Crispr Therapeutics Ag (NQ: CRSP )

    56.60 -1.32 (-2.27%)
    Streaming Delayed Price Updated: 11:31 AM EDT, Jul 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Crispr Therapeutics Ag

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    27 28 Next >
    3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
    There are a handful of different factors that could buoy its stock. 
    Via The Motley Fool
    The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
    With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy. 
    Via InvestorPlace
    7 Must-Buy Stocks if You Only Have $1,000 to Spend: May Edition
    With a modest $1,000 investment, these stocks offer the potential for market-beating gains through solid fundamentals and growth prospects. 
    Via InvestorPlace
    Is CRISPR Therapeutics a Millionaire Maker?
    The stars are aligning for it to be a leader for years to come. 
    Via The Motley Fool
    Bull Market Buys: 2 Growth Stocks to Own for the Long Run
    These biotech stocks have just launched their first products. 
    Via The Motley Fool
    Is CRISPR Therapeutics Stock a Buy?
    The gene-editing therapy specialist is rising in prominence. 
    Via The Motley Fool
    Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
    With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. 
    Via InvestorPlace
    7 No-Brainer Stocks to Buy and Hold for the Next 20 Years: May 2024
    Here are seven stocks to buy and hold that are poised for long-term growth over the next 20 years and can future-proof your portfolio. 
    Via InvestorPlace
    Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
    How much would you pay for a stock that might earn $25 a year in six years? 
    Via The Motley Fool
    2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential
    These healthcare stocks offer completely different approaches to long-term investment gains. 
    Via The Motley Fool
    The 3 Best Cathie Wood Stocks to Buy in May 2024
    Cathie Wood takes a very risky approach to investing, but she has plenty of great picks. Here are some of the best Cathie Wood stocks to buy. 
    Via InvestorPlace
    The 3 Most Undervalued Biotech Stocks to Buy in May 2024
    Three most undervalued biotech stocks to buy now will take off in the coming years and bring back continuous, hefty returns. 
    Via InvestorPlace
    Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
    Genomics is the future of medicine, creating big opportunity for some of the top genomics stock picks to buy today. 
    Via InvestorPlace
    Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
    These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
    Via InvestorPlace
    CRSP Stock Earnings: CRISPR Therapeutics Misses EPS, Misses Revenue for Q1 2024
    CRSP stock results show that CRISPR Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
    Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments. 
    Via InvestorPlace
    Exposures Product Safety
    Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street’s Radar
    The gene editing stocks are worth tuning into as some investors out there discount their innovative, albeit early-stage pipelines. 
    Via InvestorPlace
    3 Growth Stocks You’ll Kick Yourself for Not Buying Today
    Netflix, Intuit, and Vertex Pharmaceuticals are three growth stocks to buy, each positioned for significant market share and returns. 
    Via InvestorPlace
    3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
    It pays to develop novel medicines for life-threatening illnesses. 
    Via The Motley Fool
    3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
    Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion. 
    Via InvestorPlace
    Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge
    A slip in the market could give investors a rare opportunity to get some top biotech stocks to buy at a considerable discount. 
    Via InvestorPlace
    Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
    Good news could be just around the corner for two drugmakers not named Novo Nordisk. 
    Via The Motley Fool
    Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
    Vertex is broadening its portfolio. 
    Via The Motley Fool
    3 Magnificent Stocks That Could Double or More by 2030
    There's no guarantee these stocks will double by 2030, but their growth prospects look great. 
    Via The Motley Fool
    Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
    In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024. 
    Via InvestorPlace
    Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
    These rising drugmakers have serious arguments in their favor. 
    Via The Motley Fool
    Bull Market and Beyond: 3 Stocks Just Waiting to Soar
    These stocks, a bargain today, are players to hold on to for the long term. 
    Via The Motley Fool
    Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
    These companies are in the early days of their growth stories. 
    Via The Motley Fool
    3 Unstoppable Stocks to Buy Hand Over Fist in April
    These stocks have exceptionally bright prospects. 
    Via The Motley Fool
    Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
    The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia. 
    Via Investor's Business Daily
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    27 28 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.